1
|
Reghunandanan K, T P A, Krishnan N, K M D, Prasad R, Nelson-Sathi S, Chandramohanadas R. Search for novel Plasmodium falciparum PfATP4 inhibitors from the MMV Pandemic Response Box through a virtual screening approach. J Biomol Struct Dyn 2024; 42:6200-6211. [PMID: 37424150 DOI: 10.1080/07391102.2023.2232459] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2023] [Accepted: 06/27/2023] [Indexed: 07/11/2023]
Abstract
Owing to its life cycle involving multiple hosts and species-specific biological complexities, a vaccine against Plasmodium, the causative agent of Malaria remains elusive. This makes chemotherapy the only viable means to address the clinical manifestations and spread of this deadly disease. However, rapid surge in antimalarial resistance poses significant challenges to our efforts to eliminate Malaria since the best drug available to-date; Artemisinin and its combinations are also rapidly losing efficacy. Sodium ATPase (PfATP4) of Plasmodium has been recently explored as a suitable target for new antimalarials such as Cipargamin. Prior studies showed that multiple compounds from the Medicines for Malaria Venture (MMV) chemical libraries were efficient PfATP4 inhibitors. In this context, we undertook a structure- based virtual screening approach combined to Molecular Dynamic (MD) simulations to evaluate whether new molecules with binding affinity towards PfATP4 could be identified from the Pandemic Response Box (PRB), a 400-compound library of small molecules launched in 2019 by MMV. Our analysis identified new molecules from the PRB library that showed affinity for distinct binding sites including the previously known G358 site, several of which are clinically used anti-bacterial (MMV1634383, MMV1634402), antiviral (MMV010036, MMV394033) or antifungal (MMV1634494) agents. Therefore, this study highlights the possibility of exploiting PRB molecules against Malaria through abrogation of PfATP4 activity.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Keerthy Reghunandanan
- DBT-Rajiv Gandhi Centre for Biotechnology, Red Cell Diseases Laboratory, Thiruvananthapuram, India
| | - Akhila T P
- DBT-Rajiv Gandhi Centre for Biotechnology, Red Cell Diseases Laboratory, Thiruvananthapuram, India
- Manipal Academy of Higher Education, Manipal, Karnataka, India
| | - Nandini Krishnan
- DBT-Rajiv Gandhi Centre for Biotechnology, Red Cell Diseases Laboratory, Thiruvananthapuram, India
| | - Darsana K M
- DBT-Rajiv Gandhi Centre for Biotechnology, Red Cell Diseases Laboratory, Thiruvananthapuram, India
| | - Roshny Prasad
- DBT-Rajiv Gandhi Centre for Biotechnology, Bioinformatics Laboratory, Thiruvananthapuram, India
| | - Shijulal Nelson-Sathi
- DBT-Rajiv Gandhi Centre for Biotechnology, Bioinformatics Laboratory, Thiruvananthapuram, India
| | - Rajesh Chandramohanadas
- DBT-Rajiv Gandhi Centre for Biotechnology, Red Cell Diseases Laboratory, Thiruvananthapuram, India
| |
Collapse
|
2
|
Lohitha N, Kumar PH, Sarveswari S, Rathod S, Chaudhari S, Tamboli Y, Islam I, Vijayakumar V. Synthesis, Characterization, In Silico DFT, Molecular Docking, and Dynamics Simulation Studies of Phenylhydrazono Phenoxyquinolones for Their Hypoglycemic Efficacy. ACS OMEGA 2024; 9:16384-16399. [PMID: 38617610 PMCID: PMC11007768 DOI: 10.1021/acsomega.4c00079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Revised: 03/09/2024] [Accepted: 03/19/2024] [Indexed: 04/16/2024]
Abstract
A series of novel 24 phenylhydrazono phenoxyquinoline derivatives were synthesized with moderate to excellent yield and screened for their efficacy against the α-amylase enzyme through in silico studies. The structures were characterized using spectroscopic techniques such as 1HNMR, 13CNMR, and HREI-MS. Comprehensive computational studies including, drug-likeness and ADMET profiling, quantum chemical calculations, molecular docking, and molecular dynamics (MD) simulation studies, were performed. A density functional theory study of the synthesized compounds indicated a favorable reactivity profile. The synthesized novel analogues were docked against α-amylase (PDB 6OCN) enzymes to investigate the binding interactions. Based on the docking studies, one of the compounds was found to be the hit with the highest negative binding affinity for α-amylase. A MD simulation study indicated stable binding throughout the simulation.
Collapse
Affiliation(s)
- Narayanaswamy Lohitha
- Department
of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India
| | - Peruru Hemanth Kumar
- Department
of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India
| | - Sundaramoorthy Sarveswari
- Department
of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India
| | - Sanket Rathod
- Department
of Pharmaceutical Chemistry, Bharati Vidyapeeth
College of Pharmacy, Kolhapur 416013, Maharashtra, India
| | - Somdatta Chaudhari
- Department
of Pharmaceutical Chemistry, PES’s
Modern College of Pharmacy, Pune 411 044, Maharashtra, India
| | - Yasinalli Tamboli
- King
Abdullah International Medical Research Center (KAIMRC), King Saud
Bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh 14811, Saudi Arabia
| | - Imadul Islam
- King
Abdullah International Medical Research Center (KAIMRC), King Saud
Bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh 14811, Saudi Arabia
| | | |
Collapse
|
3
|
New potent ciprofloxacin-uracil conjugates as DNA gyrase and topoisomerase IV inhibitors against methicillin-resistant Staphylococcus aureus. Bioorg Med Chem 2022; 73:117004. [PMID: 36148773 DOI: 10.1016/j.bmc.2022.117004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2022] [Revised: 09/07/2022] [Accepted: 09/08/2022] [Indexed: 11/20/2022]
Abstract
A series of ciprofloxacin-uracil conjugates 5a-t were synthesized and identified by 1H NMR, 13C NMR, mass spectroscopy and elemental analyses. The antibacterial results revealed that the new derivatives exhibited better activity against Gram-positive than the Gram-negative strains; most of the target compounds exhibited good activities against S. aureus ATCC 6538. Compounds 5b and 5g possess the highest activities with MICs of 1.25 and 2.37 µM, respectively, which are more potent than the parent drug ciprofloxacin, MIC, 7.58 µM. In addition, they also exhibited potent activities against MRSA AUMC 261 with MICs, 0.031 and 0.046 µM respectively, higher than ciprofloxacin with MIC, 0.57 µM. Moreover, compounds 5b and 5g showed potent inhibitory activities against DNA gyrase (IC50 = 1.72 and 5.72 µM) and topoisomerase IV (4.36 and 7.77 µM) compared to ciprofloxacin with IC50 values 0.66 and 8.16 µM, respectively. The molecular docking study revealed that compounds 5b and 5g may formed stable interaction with the active sites of DNA gyrase and topoisomerase IV similar to ciprofloxacin. Hence, 5b and 5g are considered promising antibacterial candidated against MRSA AUMC 261 strains that requires further optimization.
Collapse
|
4
|
Xu Q, Li B, Xu Z, Jiang X, Yarmolenko M, Rogachev A, Rogachev A. PCL Based CIP-Loaded Double-Layer Films Deposited by Low-Electron Beam Dispersion Method and its Antibacterial Properties. EURASIAN CHEMICO-TECHNOLOGICAL JOURNAL 2020. [DOI: 10.18321/ectj997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
In this paper, low-electron beam dispersion (EBD) method is used to prepare a kind of double-layer films on different substrates. The bottom layer is a mechanically stirred mixture of the degradable polycaprolactone (PCL) and ciprofloxacin (CIP), and the top layer is polyurethane (PU) film. The molecular structure, chemical composition and morphology of the double-layer films were investigated by FTIR, XPS and SEM. The results showed that the surfaces of the double-layer films are uniform and the thicknesses can reach micron level. In addition, the two layers are well bonded. Then the films were sliced and immersed in PBS solution, and the time-dependent variable was used to analyze the kinetic slow-release behavior of CIP in the double-layer films by agar diffusion antibacterial experiments. It can be seen that sustained release time of CIP in the double-layer films can be up to 7 days, which is due to fact that the upper PU film working as a sealing layer helps to realize the drug slow-release. Based on the above research, the comprehensive performance of the films with the composition of PCL:CIP/PU=1:1/1 is the best.
Collapse
|
5
|
Dana S, Valissery P, Kumar S, Gurung SK, Mondal N, Dhar SK, Mukhopadhyay P. Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity. ACS Med Chem Lett 2020; 11:1450-1456. [PMID: 32676153 DOI: 10.1021/acsmedchemlett.0c00196] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 06/04/2020] [Indexed: 11/30/2022] Open
Abstract
Antimalarial drug resistance is a serious obstacle in the persistent quest to eradicate malaria. There is a need for potent chemical agents that are able to act on drug-resistant Plasmodium falciparum populations at reasonable concentrations without any related toxicity to the host. By rational drug design, we envisaged to address this issue by generating a novel hybrid drug possessing two pharmacophores that can act on two unique and independent targets within the cell. We synthesized a new class of ciprofloxacin-based hybrid molecules, which have been integrated with acridine, quinolone, sulphonamide, and cinnamoyl pharmacophores (1-4). We realized a potent chloroquinolone-ciprofloxacin-based antimalarial hybrid (2, CQ-CFX) whose mechanism of action is unlike that of its parent molecules indicating a unique biological target. CQ-CFX is not only potent against CQ-resistant and susceptible strains of Plasmodium falciparum at low nanomolar concentrations (IC50 values are 63.17 ± 1.2 nM and 25.52 ± 4.45 nM, respectively) but is also not toxic to mammalian and bacterial systems up to 20 μM and 1 μM, respectively.
Collapse
Affiliation(s)
- Srikanta Dana
- Supramolecular and Material Chemistry Lab, School of Physical Sciences, Jawaharlal Nehru University, New Delhi − 110067, India
| | | | - Sharvan Kumar
- Supramolecular and Material Chemistry Lab, School of Physical Sciences, Jawaharlal Nehru University, New Delhi − 110067, India
| | | | | | | | - Pritam Mukhopadhyay
- Supramolecular and Material Chemistry Lab, School of Physical Sciences, Jawaharlal Nehru University, New Delhi − 110067, India
| |
Collapse
|
6
|
Yi L, Lü X. New Strategy on Antimicrobial-resistance: Inhibitors of DNA Replication Enzymes. Curr Med Chem 2019; 26:1761-1787. [PMID: 29110590 DOI: 10.2174/0929867324666171106160326] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Revised: 08/31/2017] [Accepted: 10/30/2017] [Indexed: 12/12/2022]
Abstract
BACKGROUND Antimicrobial resistance is found in all microorganisms and has become one of the biggest threats to global health. New antimicrobials with different action mechanisms are effective weapons to fight against antibiotic-resistance. OBJECTIVE This review aims to find potential drugs which can be further developed into clinic practice and provide clues for developing more effective antimicrobials. METHODS DNA replication universally exists in all living organisms and is a complicated process in which multiple enzymes are involved in. Enzymes in bacterial DNA replication of initiation and elongation phases bring abundant targets for antimicrobial development as they are conserved and indispensable. In this review, enzyme inhibitors of DNA helicase, DNA primase, topoisomerases, DNA polymerase and DNA ligase were discussed. Special attentions were paid to structures, activities and action modes of these enzyme inhibitors. RESULTS Among these enzymes, type II topoisomerase is the most validated target with abundant inhibitors. For type II topoisomerase inhibitors (excluding quinolones), NBTIs and benzimidazole urea derivatives are the most promising inhibitors because of their good antimicrobial activity and physicochemical properties. Simultaneously, DNA gyrase targeted drugs are particularly attractive in the treatment of tuberculosis as DNA gyrase is the sole type II topoisomerase in Mycobacterium tuberculosis. Relatively, exploitation of antimicrobial inhibitors of the other DNA replication enzymes are primeval, in which inhibitors of topo III are even blank so far. CONCLUSION This review demonstrates that inhibitors of DNA replication enzymes are abundant, diverse and promising, many of which can be developed into antimicrobials to deal with antibioticresistance.
Collapse
Affiliation(s)
- Lanhua Yi
- College of Food Science and Engineering, Northwest A&F University, Yangling, Shaanxi Province 712100, China
| | - Xin Lü
- College of Food Science and Engineering, Northwest A&F University, Yangling, Shaanxi Province 712100, China
| |
Collapse
|
7
|
Wang R, Xu K, Shi W. Quinolone derivatives: Potential anti‐HIV agent—development and application. Arch Pharm (Weinheim) 2019; 352:e1900045. [DOI: 10.1002/ardp.201900045] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2019] [Revised: 04/28/2019] [Accepted: 05/01/2019] [Indexed: 01/03/2023]
Affiliation(s)
- Ruo Wang
- College of ChemistryFuzhou University Fuzhou Fujian People's Republic of China
| | - Kai Xu
- College of ChemistryFuzhou University Fuzhou Fujian People's Republic of China
| | - Weixiong Shi
- College of ChemistryFuzhou University Fuzhou Fujian People's Republic of China
| |
Collapse
|
8
|
Xu WC, Silverman MH, Yu XY, Wright G, Brown N. Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections. Bioorg Med Chem 2019; 27:3209-3217. [PMID: 31221610 DOI: 10.1016/j.bmc.2019.06.017] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2019] [Revised: 06/07/2019] [Accepted: 06/09/2019] [Indexed: 01/20/2023]
Abstract
Despite the growing global crisis caused by antimicrobial drug resistance among pathogenic bacteria, the number of new antibiotics, especially new chemical class of antibiotics under development is insufficient to tackle the problem. Our review focuses on an emerging class of antibacterial therapeutic agents that holds a completely novel mechanism of action, namely, inhibition of bacterial DNA polymerase IIIC. The recent entry of this new class into human trials may herald the introduction of novel drugs whose novel molecular target precludes cross-resistance with existing antibiotic classes. This review therefore examines the evolution of DNA pol IIIC inhibitors from the discovery of 6-(p-hydroxyphenylazo)uracil (HPUra) in the 1960s to the development of current first-in-class N7-substituted guanine drug candidate ACX-362E, now under clinical development for the treatment of Clostridioides difficile infection.
Collapse
Affiliation(s)
- Wei-Chu Xu
- Department of Chemistry, Worcester State University, 486 Chandler Street, Worcester, MA 01602, USA.
| | | | - Xiang Yang Yu
- Acurx Pharmaceuticals LLC, 22 Camelot Court, White Plains, NY 10603, USA
| | - George Wright
- Acurx Pharmaceuticals LLC, 22 Camelot Court, White Plains, NY 10603, USA
| | - Neal Brown
- Acurx Pharmaceuticals LLC, 22 Camelot Court, White Plains, NY 10603, USA
| |
Collapse
|
9
|
Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria. Eur J Med Chem 2019; 166:224-231. [DOI: 10.1016/j.ejmech.2019.01.062] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Revised: 01/24/2019] [Accepted: 01/24/2019] [Indexed: 11/20/2022]
|
10
|
Lagzian M, Qasemi A, Kaviani P, Mohammadi M. Identification of new promising plant-based lead compounds for inhibition of prokaryotic replicative DNA polymerases: combination of in silico and in vitro studies. J Biomol Struct Dyn 2018; 37:4222-4237. [PMID: 30526389 DOI: 10.1080/07391102.2018.1545701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Emerging widespread bacterial resistance to current antibiotics with traditional targets is one of the major global concerns. Therefore, so many investigations are exploring the potential of other druggable macromolecules of bacteria such as replication machinery components that are not addressed by previous antibiotics. DNA polymerase is the major part of this machine. However, a few studies have been done on it so far. In this respect, we report the discovery of four new plant-based leads against DNA polymerase (pol) IIIC (three leads) and pol IIIE (one lead) of Gram-positive and negative bacteria by combining a sequentially constrained high-throughput virtual screenings on Traditional Chinese Medicine Database with in vitro assays. The compounds displayed relatively good levels of inhibitory effect. They were active against their designated targets at micromolar concentrations. The IC50 values for them are ranged from 25 to 111 μM. In addition, they showed minimum inhibitory concentrations in the range of 8-128 μg/mL against five representatives of pathogenic bacteria species. However, they were inactive against Pseudomonas aeruginosa. Given these results, these leads hold promise for future modification and optimization to be more effective in lower concentrations and also against most of the important bacterial species. Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Milad Lagzian
- Department of Biology, Faculty of Science, University of Sistan and Baluchestan , Zahedan , Iran
| | - Ali Qasemi
- Department of Biology, Faculty of Science, University of Sistan and Baluchestan , Zahedan , Iran
| | - Pegah Kaviani
- Department of Biology, University of Skövde , Skövde , Sweden
| | - Malihe Mohammadi
- Department of Biology, Faculty of Science, University of Sistan and Baluchestan , Zahedan , Iran
| |
Collapse
|
11
|
Gao F, Wang P, Yang H, Miao Q, Ma L, Lu G. Recent developments of quinolone-based derivatives and their activities against Escherichia coli. Eur J Med Chem 2018; 157:1223-1248. [DOI: 10.1016/j.ejmech.2018.08.095] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Revised: 08/29/2018] [Accepted: 08/31/2018] [Indexed: 12/14/2022]
|
12
|
Gao C, Fan YL, Zhao F, Ren QC, Wu X, Chang L, Gao F. Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA). Eur J Med Chem 2018; 157:1081-1095. [PMID: 30179746 DOI: 10.1016/j.ejmech.2018.08.061] [Citation(s) in RCA: 62] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Revised: 08/21/2018] [Accepted: 08/22/2018] [Indexed: 01/10/2023]
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is the most common pathogen both in hospital and community settings, and is capable of causing serious and even fatal infections. Several antibiotics have been approved for the treatment of infections caused by MRSA, but MRSA has already developed resistance to them. More than ever, it's imperative to develop novel, high effective and fast acting anti-MRSA agents. Quinolones are one of the most common antibiotics in clinical practice used to treat various bacterial infections, and some of them displayed excellent in vitro and in vivo anti-MRSA activities, so quinolone derivatives are one of the most promising candidates. This review summarizes the recent developments of quinolone derivatives with potential activity against MRSA, and the structure-activity relationship is also discussed.
Collapse
Affiliation(s)
- Chuan Gao
- WuXi AppTec (Wuhan), Hubei, PR China
| | - Yi-Lei Fan
- Key Laboratory of Drug Prevention and Control Technology of Zhejiang Province, Zhejiang Police College, Hangzhou, PR China
| | - Feng Zhao
- WuXi AppTec (Wuhan), Hubei, PR China
| | | | - Xiang Wu
- WuXi AppTec (Wuhan), Hubei, PR China.
| | - Le Chang
- WuXi AppTec (Wuhan), Hubei, PR China.
| | - Feng Gao
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia, Canada.
| |
Collapse
|
13
|
Wang R, Yin X, Zhang Y, Yan W. Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. Eur J Med Chem 2018; 156:580-586. [PMID: 30025351 DOI: 10.1016/j.ejmech.2018.07.025] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Revised: 05/07/2018] [Accepted: 07/09/2018] [Indexed: 11/19/2022]
Abstract
Twelve novel propylene-tethered ciprofloxacin-isatin hybrids 3a-f and 4a-f were designed, synthesized and characterized by MS, HRMS, 1H NMR and 13C NMR. All hybrids were evaluated for their in vitro antimicrobial activities against representative Gram-positive, Gram-negative and mycobacterial pathogens, cytotoxicity in VERO cell line as well as metabolic stability and in vivo pharmacokinetic (PK) properties. The preliminary results indicated that all mono-isatin-ciprofloxacin hybrids exhibited excellent antibacterial activities with MIC ranging from ≤0.03 to 0.5 μg/mL against most of the tested strains. In particular, ciprofloxacin-isatin hybrid 3d was highly potent against all tested Gram-positive and Gram-negative strains including clinically important drug-resistant pathogens, which was comparable to or more potent than the parent ciprofloxacin and reference levofloxacin. Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB. Both hybrid 3b and 3d with low cytotoxicity (CC50: 64 and 256 μg/mL) also showed acceptable metabolic stability and in vivo PK properties, could act as leads for further optimization.
Collapse
Affiliation(s)
- Ruo Wang
- College of Chemistry, Fuzhou University, Fuzhou, Fujian 350116, China.
| | - Xueyang Yin
- Shanghai Key Laboratory of Green Chemistry and Chemical Processes, Department of Chemistry, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200241, China
| | - Yaohuan Zhang
- College of Chemistry, Fuzhou University, Fuzhou, Fujian 350116, China
| | - Weitao Yan
- College of Chemistry, Fuzhou University, Fuzhou, Fujian 350116, China
| |
Collapse
|
14
|
Liu B, Li F, Zhou T, Tang XQ, Hu GW. Quinoline Derivatives with Potential Activity Against Multidrug-resistant Tuberculosis. J Heterocycl Chem 2018. [DOI: 10.1002/jhet.3241] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Bi Liu
- School of Nuclear Technology and Chemistry & Biology; Hubei University of Science and Technology; Xianning People's Republic of China
| | - Fen Li
- School of Nuclear Technology and Chemistry & Biology; Hubei University of Science and Technology; Xianning People's Republic of China
| | - Ting Zhou
- School of Nuclear Technology and Chemistry & Biology; Hubei University of Science and Technology; Xianning People's Republic of China
| | - Xiu-Qin Tang
- School of Nuclear Technology and Chemistry & Biology; Hubei University of Science and Technology; Xianning People's Republic of China
| | - Guo-Wen Hu
- School of Nuclear Technology and Chemistry & Biology; Hubei University of Science and Technology; Xianning People's Republic of China
| |
Collapse
|
15
|
Jiang D. 4-Quinolone Derivatives and Their Activities Against Gram-negative Pathogens. J Heterocycl Chem 2018. [DOI: 10.1002/jhet.3244] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Dan Jiang
- School of Nuclear Technology and Chemistry & Biology; Hubei University of Science and Technology; Xianning Hubei China
| |
Collapse
|
16
|
Fan YL, Liu M, Zhang FZ, Zhang S. Design, Synthesis and In Vitro
Antitubercular Evaluation of Isatin-ciprofloxacin Hybrids with Hydrogen Bonding Capacity. J Heterocycl Chem 2018. [DOI: 10.1002/jhet.3157] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Yi-Lei Fan
- Key Laboratory of Drug Prevention and Control Technology of Zhejiang Province, Zhejiang Police College; Hangzhou People's Republic of China
| | - Min Liu
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region; Zhejiang University of Technology; Hangzhou 310014 People's Republic of China
| | - Feng-zhi Zhang
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region; Zhejiang University of Technology; Hangzhou 310014 People's Republic of China
| | - Shu Zhang
- College of Chemistry and Molecular Engineering; Peking University; People's Republic of China
| |
Collapse
|
17
|
Hamama WS, Ibrahim ME, Gooda AA, Zoorob HH. Recent advances in the chemistry of 2-chloroquinoline-3-carbaldehyde and related analogs. RSC Adv 2018; 8:8484-8515. [PMID: 35539824 PMCID: PMC9078675 DOI: 10.1039/c7ra11537g] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2017] [Accepted: 02/19/2018] [Indexed: 12/18/2022] Open
Abstract
This review highlights the recently cited research data in the literature on the chemistry of 2-chloroquinoline-3-carbaldehyde and related analogs and their applications over the period from 2013 to 2017. It covers: synthesis of quinoline ring systems and reactions adopted to construct fused or binary quinoline-cord heterocyclic systems. The biological evaluation and the synthetic applications of the target compounds were illustrated.
Collapse
Affiliation(s)
- Wafaa S Hamama
- Department of Chemistry, Faculty of Science, Mansoura University El-Gomhoria Street Mansoura 35516 Egypt +2050 2246254 +2050 2242388
| | - Mona E Ibrahim
- Department of Chemistry, Faculty of Science, Mansoura University El-Gomhoria Street Mansoura 35516 Egypt +2050 2246254 +2050 2242388
| | - Ayaa A Gooda
- Department of Chemistry, Faculty of Science, Mansoura University El-Gomhoria Street Mansoura 35516 Egypt +2050 2246254 +2050 2242388
| | - Hanafi H Zoorob
- Department of Chemistry, Faculty of Science, Mansoura University El-Gomhoria Street Mansoura 35516 Egypt +2050 2246254 +2050 2242388
| |
Collapse
|
18
|
Thamban Chandrika N, Garneau-Tsodikova S. Comprehensive review of chemical strategies for the preparation of new aminoglycosides and their biological activities. Chem Soc Rev 2018; 47:1189-1249. [PMID: 29296992 PMCID: PMC5818290 DOI: 10.1039/c7cs00407a] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
A systematic analysis of all synthetic and chemoenzymatic methodologies for the preparation of aminoglycosides for a variety of applications (therapeutic and agricultural) reported in the scientific literature up to 2017 is presented. This comprehensive analysis of derivatization/generation of novel aminoglycosides and their conjugates is divided based on the types of modifications used to make the new derivatives. Both the chemical strategies utilized and the biological results observed are covered. Structure-activity relationships based on different synthetic modifications along with their implications for activity and ability to avoid resistance against different microorganisms are also presented.
Collapse
Affiliation(s)
- Nishad Thamban Chandrika
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA.
| | | |
Collapse
|
19
|
Zhang GF, Liu X, Zhang S, Pan B, Liu ML. Ciprofloxacin derivatives and their antibacterial activities. Eur J Med Chem 2018; 146:599-612. [PMID: 29407984 DOI: 10.1016/j.ejmech.2018.01.078] [Citation(s) in RCA: 172] [Impact Index Per Article: 28.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 01/13/2018] [Accepted: 01/24/2018] [Indexed: 02/06/2023]
Abstract
Bacterial infections represent a significant health threat globally, and are responsible for the majority of hospital-acquired infections, leading to extensive mortality and burden on global healthcare systems. The second generation fluoroquinolone ciprofloxacin which exhibits excellent antimicrobial activity and pharmacokinetic properties as well as few side effects is introduced into clinical practice for the treatment of various bacterial infections for around 3 decades. The emergency and widely spread of drug-resistant pathogens making ciprofloxacin more and more ineffective, so it's imperative to develop novel antibacterials. Numerous of ciprofloxacin derivatives have been synthesized for seeking for new antibacterials, and some of them exhibited promising potency. This review aims to summarize the recent advances made towards the discovery of ciprofloxacin derivatives as antibacterial agents and the structure-activity relationship of these derivatives was also discussed.
Collapse
Affiliation(s)
- Gui-Fu Zhang
- School of Nuclear Technology and Chemistry & Biology, Hubei University of Science and Technology, Hubei, PR China
| | - Xiaofeng Liu
- Zhejiang Xianju Junye Pharmaceutical Co., Ltd, Xianju, Zhejiang, 317300, PR China; School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan, Hubei 430081, PR China.
| | - Shu Zhang
- Pony Testing International Group (Wuhan), Hubei, PR China.
| | - Baofeng Pan
- Zhejiang Xianju Junye Pharmaceutical Co., Ltd, Xianju, Zhejiang, 317300, PR China
| | - Ming-Liang Liu
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, PR China.
| |
Collapse
|
20
|
van Eijk E, Wittekoek B, Kuijper EJ, Smits WK. DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens. J Antimicrob Chemother 2018; 72:1275-1284. [PMID: 28073967 PMCID: PMC5400081 DOI: 10.1093/jac/dkw548] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
With the impending crisis of antimicrobial resistance, there is an urgent need to develop novel antimicrobials to combat difficult infections and MDR pathogenic microorganisms. DNA replication is essential for cell viability and is therefore an attractive target for antimicrobials. Although several antimicrobials targeting DNA replication proteins have been developed to date, gyrase/topoisomerase inhibitors are the only class widely used in the clinic. Given the numerous essential proteins in the bacterial replisome that may serve as a potential target for inhibitors and the relative paucity of suitable compounds, it is evident that antimicrobials targeting the replisome are underdeveloped so far. In this review, we report on the diversity of antimicrobial compounds targeting DNA replication and highlight some of the challenges in developing new drugs that target this process.
Collapse
|
21
|
4-Quinolone hybrids and their antibacterial activities. Eur J Med Chem 2017; 141:335-345. [DOI: 10.1016/j.ejmech.2017.09.050] [Citation(s) in RCA: 134] [Impact Index Per Article: 19.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2017] [Revised: 09/11/2017] [Accepted: 09/24/2017] [Indexed: 01/28/2023]
|
22
|
Zhang GF, Zhang S, Pan B, Liu X, Feng LS. 4-Quinolone derivatives and their activities against Gram positive pathogens. Eur J Med Chem 2017; 143:710-723. [PMID: 29220792 DOI: 10.1016/j.ejmech.2017.11.082] [Citation(s) in RCA: 131] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Revised: 11/24/2017] [Accepted: 11/27/2017] [Indexed: 11/17/2022]
Abstract
Gram-positive bacteria are responsible for a broad range of infectious diseases, and the emergency and wide spread of drug-resistant Gram-positive pathogens including MRSA and MRSE has caused great concern throughout the world. 4-Quinolones which are exemplified by fluoroquinolones are mainstays of chemotherapy against various bacterial infections including Gram-positive pathogen infections, and their value and role in the treatment of bacterial infections continues to expand. However, the resistance of Gram-positive organisms to 4-quinolones develops rapidly and spreads widely, making them more and more ineffective. To overcome the resistance and reduce the toxicity, numerous of 4-quinolone derivatives were synthesized and screened for their in vitro and in vivo activities against Gram-positive pathogens, and some of them exhibited excellent potency. This review aims to outlines the recent advances made towards the discovery of 4-quinolone-based derivatives as anti-Gram-positive pathogens agents and the critical aspects of design as well as the structure-activity relationship of these derivatives. The enriched SAR paves the way to the further rational development of 4-quinolones with a unique mechanism of action different from that of the currently used drugs to overcome the resistance, well-tolerated and low toxic profiles.
Collapse
Affiliation(s)
- Gui-Fu Zhang
- School of Nuclear Technology and Chemistry & Life Science, Hubei University of Science and Technology, Hubei, PR China
| | - Shu Zhang
- Pony Testing International Group (Wuhan), Hubei, PR China
| | - Baofeng Pan
- Zhejiang Xianju Junye Pharmaceutical Co., Ltd, Xianju, Zhejiang, 317300, PR China
| | - Xiaofeng Liu
- Zhejiang Xianju Junye Pharmaceutical Co., Ltd, Xianju, Zhejiang, 317300, PR China; School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan, Hubei, 430081, PR China.
| | - Lian-Shun Feng
- Synthetic and Functional Biomolecules Center, Peking University, Beijing, PR China.
| |
Collapse
|
23
|
Kour P, Kumar A, Sharma R, Chib R, Ali Khan I, Rai VK. Synthesis of 2-amino-4H-chromen-4-ylphosphonates and β-phosphonomalonates via tandem Knoevenagel–Phospha-Michael reaction and antimicrobial evaluation of newly synthesized β-phosphonomalonates. RESEARCH ON CHEMICAL INTERMEDIATES 2017. [DOI: 10.1007/s11164-017-3077-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
Klahn P, Brönstrup M. Bifunctional antimicrobial conjugates and hybrid antimicrobials. Nat Prod Rep 2017; 34:832-885. [PMID: 28530279 DOI: 10.1039/c7np00006e] [Citation(s) in RCA: 119] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Covering: up to the end of 2016Novel antimicrobial drugs are continuously needed to counteract bacterial resistance development. An innovative molecular design strategy for novel antibiotic drugs is based on the hybridization of an antibiotic with a second functional entity. Such conjugates can be grouped into two major categories. In the first category (antimicrobial hybrids), both functional elements of the hybrid exert antimicrobial activity. Due to the dual targeting, resistance development can be significantly impaired, the pharmacokinetic properties can be superior compared to combination therapies with the single antibiotics, and the antibacterial potency is often enhanced in a synergistic manner. In the second category (antimicrobial conjugates), one functional moiety controls the accumulation of the other part of the conjugate, e.g. by mediating an active transport into the bacterial cell or blocking the efflux. This approach is mostly applied to translocate compounds across the cell envelope of Gram-negative bacteria through membrane-embedded transporters (e.g. siderophore transporters) that provide nutrition and signalling compounds to the cell. Such 'Trojan Horse' approaches can expand the antibacterial activity of compounds against Gram-negative pathogens, or offer new options for natural products that could not be developed as standalone antibiotics, e.g. due to their toxicity.
Collapse
Affiliation(s)
- P Klahn
- Department for Chemical Biology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, Germany. and Institute for Organic Chemistry, Technische Universität Braunschweig, Hagenring 30, 38106 Braunschweig, Germany.
| | - M Brönstrup
- Department for Chemical Biology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, Germany.
| |
Collapse
|
25
|
Synthesis and Evaluation of Ciprofloxacin-Nitroxide Conjugates as Anti-Biofilm Agents. Molecules 2016; 21:molecules21070841. [PMID: 27355936 PMCID: PMC6273952 DOI: 10.3390/molecules21070841] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Revised: 06/17/2016] [Accepted: 06/21/2016] [Indexed: 12/14/2022] Open
Abstract
As bacterial biofilms are often refractory to conventional antimicrobials, the need for alternative and/or novel strategies for the treatment of biofilm related infections has become of paramount importance. Herein, we report the synthesis of novel hybrid molecules comprised of two different hindered nitroxides linked to the piperazinyl secondary amine of ciprofloxacin via a tertiary amine linker achieved utilising reductive amination. The corresponding methoxyamine derivatives were prepared alongside their radical-containing counterparts as controls. Subsequent biological evaluation of the hybrid compounds on preformed P. aeruginosa flow cell biofilms divulged significant dispersal and eradication abilities for ciprofloxacin-nitroxide hybrid compound 10 (up to 95% eradication of mature biofilms at 40 μM). Importantly, these hybrids represent the first dual-action antimicrobial-nitroxide agents, which harness the dispersal properties of the nitroxide moiety to circumvent the well-known resistance of biofilms to treatment with antimicrobial agents.
Collapse
|
26
|
Chandrika NT, Garneau-Tsodikova S. A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides. MEDCHEMCOMM 2015; 7:50-68. [PMID: 27019689 PMCID: PMC4806794 DOI: 10.1039/c5md00453e] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Since the discovery of the first aminoglycoside (AG), streptomycin, in 1943, these broad-spectrum antibiotics have been extensively used for the treatment of Gram-negative and Gram-positive bacterial infections. The inherent toxicity (ototoxicity and nephrotoxicity) associated with their long-term use as well as the emergence of resistant bacterial strains have limited their usage. Structural modifications of AGs by AG-modifying enzymes, reduced target affinity caused by ribosomal modification, and decrease in their cellular concentration by efflux pumps have resulted in resistance towards AGs. However, the last decade has seen a renewed interest among the scientific community for AGs as exemplified by the recent influx of scientific articles and patents on their therapeutic use. In this review, we use a non-conventional approach to put forth this renaissance on AG development/application by summarizing all patents filed on AGs from 2011-2015 and highlighting some related publications on the most recent work done on AGs to overcome resistance and improving their therapeutic use while reducing ototoxicity and nephrotoxicity. We also present work towards developing amphiphilic AGs for use as fungicides as well as that towards repurposing existing AGs for potential newer applications.
Collapse
Affiliation(s)
- Nishad Thamban Chandrika
- University of Kentucky, Department of Pharmaceutical Sciences, 789 South Limestone Street, Lexington, KY, USA. Fax: 859-257-7585; Tel: 859-218-1686
| | - Sylvie Garneau-Tsodikova
- University of Kentucky, Department of Pharmaceutical Sciences, 789 South Limestone Street, Lexington, KY, USA. Fax: 859-257-7585; Tel: 859-218-1686
| |
Collapse
|
27
|
Paneth A, Stączek P, Plech T, Strzelczyk A, Dzitko K, Wujec M, Kuśmierz E, Kosikowska U, Grzegorczyk A, Paneth P. Biological evaluation and molecular modelling study of thiosemicarbazide derivatives as bacterial type IIA topoisomerases inhibitors. J Enzyme Inhib Med Chem 2015; 31:14-22. [PMID: 25792505 DOI: 10.3109/14756366.2014.1003214] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
In the present article, we describe the inhibitory potency of nine thiosemicarbazide derivatives against bacterial type IIA topoisomerases, their antibacterial profile and molecular modelling evaluation. We found that one of the tested compounds, compound 7, significantly inhibits activity of Staphylococcus aureus DNA gyrase with an IC(50) below 15 μM. Besides, this compound displays antibacterial activity on reference Staphylococuss spp. and Enterococcus faecalis strains as well as clinical S. aureus isolates at non-cytotoxic concentrations in mammalian cells with MIC values ranging from 16 to 32 μg/mL thereby indicating, in some cases, equipotent or even more effective action than standard drugs such as vancomycin, ampicillin and nitrofurantoin. The computational studies showed that both molecular geometry and the electron density distribution have a great impact on antibacterial activity of thiosemicarbazide derivatives.
Collapse
Affiliation(s)
- Agata Paneth
- a Department of Organic Chemistry , Medical University of Lublin , Poland .,e Institute of Applied Radiation Chemistry, Lodz University of Technology , Poland
| | | | - Tomasz Plech
- a Department of Organic Chemistry , Medical University of Lublin , Poland
| | | | - Katarzyna Dzitko
- c Department of Immunoparasitology , University of Łódź , Poland
| | - Monika Wujec
- a Department of Organic Chemistry , Medical University of Lublin , Poland
| | - Edyta Kuśmierz
- a Department of Organic Chemistry , Medical University of Lublin , Poland
| | - Urszula Kosikowska
- d Department of Pharmaceutical Microbiology , Medical University of Lublin , Poland , and
| | - Agnieszka Grzegorczyk
- d Department of Pharmaceutical Microbiology , Medical University of Lublin , Poland , and
| | - Piotr Paneth
- e Institute of Applied Radiation Chemistry, Lodz University of Technology , Poland
| |
Collapse
|
28
|
Hou Z, Zhou Y, Li J, Zhang X, Shi X, Xue X, Li Z, Ma B, Wang Y, Li M, Luo X. Selective in vivo and in vitro activities of 3,3'-4-nitrobenzylidene-bis-4-hydroxycoumarin against methicillin-resistant Staphylococcus aureus by inhibition of DNA polymerase III. Sci Rep 2015; 5:13637. [PMID: 26323712 PMCID: PMC5378903 DOI: 10.1038/srep13637] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2015] [Accepted: 07/31/2015] [Indexed: 01/08/2023] Open
Abstract
As the persistent resistance of Staphylococcus aureus to available antibiotics is associated with high infection incidence, mortality rate and treatment cost, novel antibacterial agents with innovative therapeutic targets must be developed. 3,3′-(4-Nitrobenzylidene)-bis-(4-hydroxycoumarin) (NBH), a dicoumarin derivative, was reported to exert antibacterial activity. This study investigated the underlying mechanisms of in vivo and in vitro activities of NBH against S. aureus. NBH exerted bactericidal effects against the tested S. aureus and Staphylococcus epidermidis strains in vitro, with low cytotoxicity and resistance and high plasma stability. NBH also exhibited therapeutic effects in vivo on septicaemic mice. Results of molecular docking and analysis on morphological change, DNA production and polymerase inhibition suggested that DNA polymerase could be the target of NBH. These findings indicated that dicoumarin derivatives, which interfere with DNA replication, could be developed as a potential agent against S. aureus, particularly methicillin-resistant strains.
Collapse
Affiliation(s)
- Zheng Hou
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
| | - Ying Zhou
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
| | - Jing Li
- School of Chemical Engineering, Xi'an University, Xi'an, Shaanxi, 710065, China
| | - Xinlei Zhang
- School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
| | - Xin Shi
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
| | - Xiaoyan Xue
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
| | - Zhi Li
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
| | - Bo Ma
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
| | - Yukun Wang
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
| | - Mingkai Li
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
| | - Xiaoxing Luo
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
| |
Collapse
|
29
|
Tevyashova AN, Olsufyeva EN, Preobrazhenskaya MN. Design of dual action antibiotics as an approach to search for new promising drugs. RUSSIAN CHEMICAL REVIEWS 2015. [DOI: 10.1070/rcr4448] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
30
|
Karad SC, Purohit VB, Raval DK, Kalaria PN, Avalani JR, Thakor P, Thakkar VR. Green synthesis and pharmacological screening of polyhydroquinoline derivatives bearing a fluorinated 5-aryloxypyrazole nucleus. RSC Adv 2015. [DOI: 10.1039/c5ra00388a] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Green synthesis, biological evaluation and SAR study of polyhydroquinoline scaffold bearing fluorinated 5-aryloxypyrazole nucleus is discussed.
Collapse
Affiliation(s)
- Sharad C. Karad
- Department of Chemistry
- Sardar Patel University
- Vallabh Vidyanagar-388120
- India
| | - Vishal B. Purohit
- Department of Chemistry
- Sardar Patel University
- Vallabh Vidyanagar-388120
- India
| | - Dipak K. Raval
- Department of Chemistry
- Sardar Patel University
- Vallabh Vidyanagar-388120
- India
| | - Piyush N. Kalaria
- Department of Chemistry
- Sardar Patel University
- Vallabh Vidyanagar-388120
- India
| | - Jemin R. Avalani
- Department of Chemistry
- Sardar Patel University
- Vallabh Vidyanagar-388120
- India
| | - Parth Thakor
- B. R. Doshi School of Biosciences
- Sardar Patel Maidan
- Satellite Campus
- Sardar Patel University
- Vallabh Vidyanagar-388120
| | - Vasudev R. Thakkar
- B. R. Doshi School of Biosciences
- Sardar Patel Maidan
- Satellite Campus
- Sardar Patel University
- Vallabh Vidyanagar-388120
| |
Collapse
|
31
|
Gao LZ, Xie YS, Li T, Huang WL, Hu GQ. Synthesis and antibacterial activity of novel [1,2,4]triazolo[3,4-h][1,8]naphthyridine-7-carboxylic acid derivatives. CHINESE CHEM LETT 2015. [DOI: 10.1016/j.cclet.2014.09.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
32
|
O'Connell KMG, Hodgkinson JT, Sore HF, Welch M, Salmond GPC, Spring DR. Die Bekämpfung multiresistenter Bakterien: aktuelle Strategien zur Entdeckung neuer Antibiotika. Angew Chem Int Ed Engl 2013. [DOI: 10.1002/ange.201209979] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
33
|
O'Connell KMG, Hodgkinson JT, Sore HF, Welch M, Salmond GPC, Spring DR. Combating Multidrug-Resistant Bacteria: Current Strategies for the Discovery of Novel Antibacterials. Angew Chem Int Ed Engl 2013; 52:10706-33. [DOI: 10.1002/anie.201209979] [Citation(s) in RCA: 310] [Impact Index Per Article: 28.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Revised: 02/25/2013] [Indexed: 11/07/2022]
|
34
|
Kathrotiya HG, Patel MP. Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents. Eur J Med Chem 2013; 63:675-84. [DOI: 10.1016/j.ejmech.2013.03.017] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2012] [Revised: 12/28/2012] [Accepted: 03/08/2013] [Indexed: 10/27/2022]
|
35
|
Robinson A, Causer RJ, Dixon NE. Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target. Curr Drug Targets 2012; 13:352-72. [PMID: 22206257 PMCID: PMC3290774 DOI: 10.2174/138945012799424598] [Citation(s) in RCA: 87] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2011] [Revised: 11/03/2011] [Accepted: 11/05/2011] [Indexed: 11/22/2022]
Abstract
New antibiotics with novel modes of action are required to combat the growing threat posed by multi-drug resistant bacteria. Over the last decade, genome sequencing and other high-throughput techniques have provided tremendous insight into the molecular processes underlying cellular functions in a wide range of bacterial species. We can now use these data to assess the degree of conservation of certain aspects of bacterial physiology, to help choose the best cellular targets for development of new broad-spectrum antibacterials. DNA replication is a conserved and essential process, and the large number of proteins that interact to replicate DNA in bacteria are distinct from those in eukaryotes and archaea; yet none of the antibiotics in current clinical use acts directly on the replication machinery. Bacterial DNA synthesis thus appears to be an underexploited drug target. However, before this system can be targeted for drug design, it is important to understand which parts are conserved and which are not, as this will have implications for the spectrum of activity of any new inhibitors against bacterial species, as well as the potential for development of drug resistance. In this review we assess similarities and differences in replication components and mechanisms across the bacteria, highlight current progress towards the discovery of novel replication inhibitors, and suggest those aspects of the replication machinery that have the greatest potential as drug targets.
Collapse
Affiliation(s)
- Andrew Robinson
- School of Chemistry, University of Wollongong, NSW 2522, Australia
| | | | | |
Collapse
|
36
|
Butler MM, Shinabarger DL, Citron DM, Kelly CP, Dvoskin S, Wright GE, Feng H, Tzipori S, Bowlin TL. MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Chemother 2012; 56:4786-92. [PMID: 22733075 PMCID: PMC3421853 DOI: 10.1128/aac.00508-12] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2012] [Accepted: 06/19/2012] [Indexed: 12/18/2022] Open
Abstract
Clostridium difficile infection (CDI) causes moderate to severe disease, resulting in diarrhea and pseudomembranous colitis. CDI is difficult to treat due to production of inflammation-inducing toxins, resistance development, and high probability of recurrence. Only two antibiotics are approved for the treatment of CDI, and the pipeline for therapeutic agents contains few new drugs. MBX-500 is a hybrid antibacterial, composed of an anilinouracil DNA polymerase inhibitor linked to a fluoroquinolone DNA gyrase/topoisomerase inhibitor, with potential as a new therapeutic for CDI treatment. Since MBX-500 inhibits three bacterial targets, it has been previously shown to be minimally susceptible to resistance development. In the present study, the in vitro and in vivo efficacies of MBX-500 were explored against the Gram-positive anaerobe, C. difficile. MBX-500 displayed potency across nearly 50 isolates, including those of the fluoroquinolone-resistant, toxin-overproducing NAP1/027 ribotype, performing as well as comparator antibiotics vancomycin and metronidazole. Furthermore, MBX-500 was a narrow-spectrum agent, displaying poor activity against many other gut anaerobes. MBX-500 was active in acute and recurrent infections in a toxigenic hamster model of CDI, exhibiting full protection against acute infections and prevention of recurrence in 70% of the animals. Hamsters treated with MBX-500 displayed significantly greater weight gain than did those treated with vancomycin. Finally, MBX-500 was efficacious in a murine model of CDI, again demonstrating a fully protective effect and permitting near-normal weight gain in the treated animals. These selective anti-CDI features support the further development of MBX 500 for the treatment of CDI.
Collapse
|
37
|
Sanyal G, Doig P. Bacterial DNA replication enzymes as targets for antibacterial drug discovery. Expert Opin Drug Discov 2012; 7:327-39. [PMID: 22458504 DOI: 10.1517/17460441.2012.660478] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
INTRODUCTION The bacterial replisome is composed of a large number of enzymes, which work in exquisite coordination to accomplish chromosomal replication. Effective inhibition inside the bacterial cell of any of the 'essential' enzymes of the DNA replication pathway should be detrimental to cell survival. AREAS COVERED This review covers DNA replication enzymes that have been shown to have a potential for delivering antibacterial compounds or drug candidates including: type II topoisomerases, a clinically validated target family, and DNA ligase, which has yielded inhibitors with in vivo efficacy. A few of the 'replisome' enzymes that are structurally and functionally well characterized and have been subjects of antibacterial discovery efforts are also discussed. EXPERT OPINION Identification of several essential genes in the bacterial replication pathway raised hopes that targeting these gene products would lead to novel antibacterials. However, none of these novel, single gene targets have delivered antibacterial drug candidates into clinical trials. This lack of productivity may be due to the target properties and inhibitor identification approaches employed. For DNA primase, DNA helicase and other replisome targets, with the exception of DNA ligase, the exploitation of structure for lead generation has not been tested to the same extent that it has for DNA gyrase. Utilization of structural information should be considered to augment HTS efforts and initiate fragment-based lead generation. The complex protein-protein interactions involved in regulation of replication may explain why biochemical approaches have been less productive for some replisome targets than more independently functioning targets such as DNA ligase or DNA gyrase.
Collapse
Affiliation(s)
- Gautam Sanyal
- Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Dr, Waltham, MA 02451, USA.
| | | |
Collapse
|
38
|
Abstract
There is a clear and urgent need for novel antibacterial agents that can address the concerns of growing resistance. This article details recent patent activity within the antibiotic field based on the emerging strategy of a multivalent approach to drug discovery. A range of heterodimer antibiotics are discussed, which consist of two antibacterial chemical classes covalently linked to afford compounds with the potential to engage multiple mechanisms of action. The possible benefits of such compounds include activity against drug-resistant bacteria, enhanced efficacy and duration, an expanded spectrum of activity and reduced potential for generating bacterial resistance. This exciting approach towards novel heterodimer antibiotics holds significant promise, but must overcome a range of challenges before yielding a successful medicine. Progress to date is encouraging and has resulted in three compounds entering clinical trials.
Collapse
|
39
|
|
40
|
Sachin K, Kim EM, Cheong SJ, Jeong HJ, Lim ST, Sohn MH, Kim DW. Synthesis of N₄'-[¹⁸F]fluoroalkylated ciprofloxacin as a potential bacterial infection imaging agent for PET study. Bioconjug Chem 2010; 21:2282-8. [PMID: 21049983 DOI: 10.1021/bc1002983] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Syntheses and evaluation of fluoroalkylated ciprofloxacin analogues are described. Among these analogues, N₄'-3-fluoropropylciprofloxacin (16) showed the most efficient antibacterial activity against E. coli strains (DH5α and TOP10) and a high binding affinity for DNA gyrase of bacteria. To develop bacteria-specific infection imaging agents for positron emission tomography (PET), no-carrier-added N₄-3-[¹⁸F]fluoropropylciprofloxacin ([¹⁸F]16) was prepared in two steps from N₄-3-methanesufonyloxypropylciprofloxacin, resulting in a 40% radiochemical yield (decay corrected for 100 min) via the tert-alcohol media radiofluorination protocol with high radiochemical purity (> 99%) as well as high specific activity (149 ± 75 GBq/μmol). The agent was stable (> 90%), as shown by an in vitro human serum stability assay. A bacterial uptake and blocking study of [¹⁸F]16 using authentic compound 16 in TOP10 cells demonstrated its high specific bacterial uptake. The results suggest that this radiotracer holds promise as a useful bacterial infection radiopharmaceutical for PET imaging.
Collapse
Affiliation(s)
- Kalme Sachin
- Department of Nuclear Medicine, Cyclotron Research Center, Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Jeonbuk 561-712, Korea
| | | | | | | | | | | | | |
Collapse
|
41
|
Pokrovskaya V, Baasov T. Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance. Expert Opin Drug Discov 2010; 5:883-902. [DOI: 10.1517/17460441.2010.508069] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Varvara Pokrovskaya
- Technion – Israel Institute of Technology, The Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Haifa 32000, Israel ;
| | - Timor Baasov
- Technion – Israel Institute of Technology, The Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Haifa 32000, Israel ;
| |
Collapse
|
42
|
Wiles JA, Bradbury BJ, Pucci MJ. New quinolone antibiotics: a survey of the literature from 2005 to 2010. Expert Opin Ther Pat 2010; 20:1295-319. [DOI: 10.1517/13543776.2010.505922] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
43
|
Pieroni M, Dimovska M, Brincat JP, Sabatini S, Carosati E, Massari S, Kaatz GW, Fravolini A. From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps. J Med Chem 2010; 53:4466-80. [PMID: 20446747 DOI: 10.1021/jm1003304] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The thiopyranopyridine moiety was synthesized as a new heterocyclic base to be inserted at the C-7 position of selected quinolone nuclei followed by a determination of antibacterial activity against strains of Staphylococcus aureus. Selected thiopyranopyridinylquinolones showed significant antimicrobial activity, including strains having mutations in gyrA and grlA as well as other strains overexpressing the NorA multidrug (MDR) efflux pump. Most derivatives did not appear to be NorA substrates. The effect of the thiopyranopyridinyl substituent on making these quinolones poor substrates for NorA was investigated further. Several quinolone ester intermediates, devoid of any intrinsic antibacterial activity, were tested for their abilities to inhibit the activities of NorA (MFS family) and MepA (MATE family) S. aureus MDR efflux pumps. Selected quinolone esters were capable of inhibiting both MDR pumps more efficiently than the reference compound reserpine. Moreover, they also were able to restore, and even enhance, the activity of ciprofloxacin toward some genetically modified resistant S. aureus strains.
Collapse
Affiliation(s)
- Marco Pieroni
- Dipartimento di Chimica e Tecnologia del Farmaco, Università degli Studi di Perugia, 06123 Perugia, Italy
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Fasani E, Manet I, Capobianco ML, Monti S, Pretali L, Albini A. Fluoroquinolones as potential photochemotherapeutic agents: covalent addition to guanosine monophosphate. Org Biomol Chem 2010; 8:3621-3. [PMID: 20571620 DOI: 10.1039/c0ob00056f] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The triplet aryl cation photochemically generated from fluoroquinolones bearing a fluoro atom at position 8 attacks guanosine monophosphate (k(r) > 10(9) M(-1)s(-1)) and forms covalent adducts. The reaction is a model for the implementation of oxygen-independent photochemotherapy.
Collapse
Affiliation(s)
- Elisa Fasani
- Dip. Chimica Organica, Università di Pavia, viale Taramelli 10, 27100, Italy
| | | | | | | | | | | |
Collapse
|
45
|
Sissi C, Palumbo M. In front of and behind the replication fork: bacterial type IIA topoisomerases. Cell Mol Life Sci 2010; 67:2001-24. [PMID: 20165898 PMCID: PMC11115839 DOI: 10.1007/s00018-010-0299-5] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2009] [Revised: 01/26/2010] [Accepted: 02/01/2010] [Indexed: 01/03/2023]
Abstract
Topoisomerases are vital enzymes specialized in controlling DNA topology, in particular supercoiling and decatenation, to properly handle nucleic acid packing and cell dynamics. The type IIA enzymes act by cleaving both strands of a double helix and having another strand from the same or another molecule cross the DNA gate before a re-sealing event completes the catalytic cycle. Here, we will consider the two types of IIA prokaryotic topoisomerases, DNA Gyrase and Topoisomerase IV, as crucial regulators of bacterial cell cycle progression. Their synergistic action allows control of chromosome packing and grants occurrence of functional transcription and replication processes. In addition to displaying a fascinating molecular mechanism of action, which transduces chemical energy into mechanical energy by means of large conformational changes, these enzymes represent attractive pharmacological targets for antibacterial chemotherapy.
Collapse
Affiliation(s)
- Claudia Sissi
- Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131, Padua, Italy.
| | | |
Collapse
|
46
|
Taylor RR, Twin HC, Wen WW, Mallot RJ, Lough AJ, Gray-Owen SD, Batey RA. Substituted 2,5-diazabicyclo[4.1.0]heptanes and their application as general piperazine surrogates: synthesis and biological activity of a Ciprofloxacin analogue. Tetrahedron 2010. [DOI: 10.1016/j.tet.2010.02.046] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
47
|
Synthesis and antibacterial evaluation of isoxazolinyl oxazolidinones: Search for potent antibacterial. Bioorg Med Chem Lett 2009; 19:3573-6. [DOI: 10.1016/j.bmcl.2009.04.133] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2009] [Revised: 04/16/2009] [Accepted: 04/29/2009] [Indexed: 10/20/2022]
|
48
|
Pokrovskaya V, Belakhov V, Hainrichson M, Yaron S, Baasov T. Design, Synthesis, and Evaluation of Novel Fluoroquinolone−Aminoglycoside Hybrid Antibiotics. J Med Chem 2009; 52:2243-54. [DOI: 10.1021/jm900028n] [Citation(s) in RCA: 103] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Varvara Pokrovskaya
- The Edith and Joseph Fisher Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, and Department of Biotechnology and Food Engineering, Technion—Israel Institute of Technology, Haifa 32000, Israel
| | - Valery Belakhov
- The Edith and Joseph Fisher Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, and Department of Biotechnology and Food Engineering, Technion—Israel Institute of Technology, Haifa 32000, Israel
| | - Mariana Hainrichson
- The Edith and Joseph Fisher Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, and Department of Biotechnology and Food Engineering, Technion—Israel Institute of Technology, Haifa 32000, Israel
| | - Sima Yaron
- The Edith and Joseph Fisher Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, and Department of Biotechnology and Food Engineering, Technion—Israel Institute of Technology, Haifa 32000, Israel
| | - Timor Baasov
- The Edith and Joseph Fisher Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, and Department of Biotechnology and Food Engineering, Technion—Israel Institute of Technology, Haifa 32000, Israel
| |
Collapse
|
49
|
Barbachyn MR. Recent Advances in the Discovery of Hybrid Antibacterial Agents. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2008. [DOI: 10.1016/s0065-7743(08)00017-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
|
50
|
Abstract
Antibacterial discovery research has been driven, medically, commercially and intellectually, by the need for new therapeutics that are not subject to the resistance mechanisms that have evolved to combat previous generations of antibacterial agents. This need has often been equated with the identification and exploitation of novel targets. But efforts towards discovery and development of inhibitors of novel targets have proved frustrating. It might be that the 'good old targets' are qualitatively different from the crop of all possible novel targets. What has been learned from existing targets that can be applied to the quest for new antibacterials?
Collapse
Affiliation(s)
- Lynn L Silver
- LL Silver Consulting, Springfield, New Jersey 07081, USA.
| |
Collapse
|